Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Shares of EyeGate Pharmaceuticals (NASDAQ: EYEG) are rallying premarket on Monday after the company revealed it will acquire Panoptes Pharma, a privately-held clinical-stage biotech company.
EyeGate said the acquisition will transform its pipeline with the addition of PP-001, a “next-generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with potential best-in-class picomolar potency.”
EyeGate will pay $4 million for Panoptes, which will consist of EyeGate common stock, preferred stock and cash. A further $1.5 million in EyeGate common stock will be issued after 18 months, subject to certain conditions.
The transaction also includes two cash or share earn-out provisions, each for an additional payment of up to $4,750,000 contingent upon 1) the enrollment and randomisation of a first patient into the first Phase III pivotal study of any Panoptes ophthalmic product with the FDA, and 2) approval of a New Drug Application by the FDA for any Panoptes ophthalmic product.
“The acquisition of Panoptes propels the EyeGate pipeline forward to include a de-risked clinical-stage candidate with broad potential across a diverse range of ocular, autoimmune and neurological indications,” said Stephen From, CEO of EyeGate.
The news has resulted in a rally for EyeGate’s share price. It is currently up 85.87% premarket at $6.60 following Friday's close at $3.57.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .